News

The Next Chapter for Real World Evidence: Validating Data with the Patient Voice

In June 2020, in accordance with the 21st Century Cures Act of 2016 and the Prescription Drug User Fee Act (PDUFA), the U.S. Food and Drug Administration (FDA) launched Project Patient Voice. This patient-focused drug development initiative facilitates systematic approaches to collecting and using meaningful patient and caregiver input, to better inform medical product development and regulatory decision-making, taking the use of real-world evidence (RWE) to a new level.

ARN & Trio Health Form ARN Clinical Research

American Rheumatology Network (ARN), in partnership with Trio Health, launched ARN Clinical Research to transform drug development for rheumatology research. This technology-driven solution will unite the power of the ARN network with Trio’s proven data management technologies to develop a real-time integrated platform enabling manufacturers to rapidly achieve their goals.

ARN Announces Michael Cooper as Chief Executive Officer

We are pleased to announce we have appointed Michael Cooper as American Rheumatology Network’s (ARN) new CEO, effective immediately. Michael’s appointment reflects ARN’s current state: enthusiastic and ready to take on the future after another strong year of growth and success. We are excited for Michael to guide our company using his unique experience in …

ARN Announces Michael Cooper as Chief Executive Officer Read More »

ARN & AHG Position Statement: “Most Favored Nation Model”

To Our Members and Partners, American Rheumatology Network (ARN) and Articularis Healthcare Group Inc., (AHG) stands with the rheumatology community, with the Coalition of State Rheumatology Organizations (CSRO), and with the National Organization of Rheumatology Management (NORM) in firm opposition to the CMS “Most Favored Nation Model.” This model poses an immediate threat to patient …

ARN & AHG Position Statement: “Most Favored Nation Model” Read More »

Affiliate AHG Physician Publishes “Precision Medicine: Redefining Care for Rheumatoid Arthritis”

Each patient is unique. What if their treatment path was too? That possibility is at the core of precision medicine. J. Eugene Huffstutter, MD Precision medicine allows patients to receive treatment based on their personal, genetic makeup. It is commonly associated with oncology, where therapies can address patients’ genetic biomarkers rather than just the location …

Affiliate AHG Physician Publishes “Precision Medicine: Redefining Care for Rheumatoid Arthritis” Read More »

Why do Patients Discontinue Treatment?

The ARN-Trio registry recently hosted a webinar unlocking deep insights into the “Why” behind patients discontinuing prescription therapy. The recorded webinar is available here. ARN-Trio registry uniquely employs trained chart abstractors to review unstructured data for the 369,000 patients in the registry, identifying the actual reasons for discontinuations as recorded in the visit notes. Traditionally, …

Why do Patients Discontinue Treatment? Read More »

ARN-Trio Registry Highlights Major Shifts in Infliximab Biosimilar Use

Analysis of the American Rheumatology Network-Trio Health (ARN-Trio) registry finds a surge in new prescriptions for Merck’s Renflexis infliximab biosimilar. The ARN-Trio registry is the first rheumatology registry to combine pharmacy dispensing data with electronic medical records (EMR) to provide unparalleled real-world insights. ARN-Trio is the largest registry of biosimilar use in community rheumatology practice, …

ARN-Trio Registry Highlights Major Shifts in Infliximab Biosimilar Use Read More »

Scroll to Top

How Can We Help You?